Iqvia Holdings Inc (NYSE:IQV) has been given an average rating of “Buy” by the twenty-two analysts that are currently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $110.40.
Several equities research analysts recently issued reports on the company. Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating in a report on Wednesday, April 18th. Argus lifted their price objective on Iqvia from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Monday, April 9th. ValuEngine cut Iqvia from a “buy” rating to a “hold” rating in a report on Tuesday, April 3rd. Goldman Sachs upgraded Iqvia from a “neutral” rating to a “buy” rating in a report on Friday, April 13th. Finally, Mizuho set a $97.00 target price on Iqvia and gave the stock a “hold” rating in a report on Wednesday, January 24th.
Shares of Iqvia stock traded up $1.73 on Wednesday, hitting $99.00. The company’s stock had a trading volume of 137,800 shares, compared to its average volume of 1,059,663. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 1.21. Iqvia has a 1 year low of $81.43 and a 1 year high of $110.67. The firm has a market cap of $20,258.43, a PE ratio of 22.54, a P/E/G ratio of 1.65 and a beta of 0.63.
In other news, insider Robert Parks sold 896 shares of Iqvia stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $105.73, for a total transaction of $94,734.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James H. Erlinger III sold 10,000 shares of Iqvia stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,527 shares of company stock worth $1,257,834. Corporate insiders own 6.00% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. purchased a new stake in Iqvia in the fourth quarter valued at approximately $123,000. Focused Wealth Management Inc purchased a new stake in Iqvia in the fourth quarter valued at approximately $166,000. Valeo Financial Advisors LLC purchased a new stake in Iqvia in the fourth quarter valued at approximately $170,000. IFP Advisors Inc purchased a new stake in Iqvia in the fourth quarter valued at approximately $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Iqvia in the fourth quarter valued at approximately $209,000. 92.58% of the stock is currently owned by hedge funds and other institutional investors.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.